Pacific Edge Full Year Result to be Announced 21 May 2024

1 May 2024
PACIFIC EDGE FULL YEAR RESULT TO BE ANNOUNCED 21 MAY
2024
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today
advises that its full year results for the 12 months to 31 March 2024 (FY24) will be released on
Tuesday 21 May 2024, prior to 10am.

This will be followed by an Investor and Analyst conference call at 11.00am (NZST). This
investor briefing will be available via webcast by the following link:
www.virtualmeeting.co.nz/pebfy24 or by phone on the following toll free numbers:

New Zealand: 0800 005 652
Australia: 1800 953 093
USA & Canada: 888 672-2415

Conference ID 7745991

Questions
Questions can be submitted online in writing via the Webcast platform or verbally via the audio
call system when prompted.

If you have any queries regarding the results announcement or the conference call, please
contact Stacey Stanley on stacey.stanley@pelnz.com.

ENDS


Approved for release by:

Grant Gibson
Chief Financial Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com
Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance
of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes
more than 20 peer reviewed publications for primary detection, surveillance, adjudication of
atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous
ongoing and planned clinical studies to generate an ever-increasing body of clinical utility
evidence supporting adoption and use in the clinic to improve patient health outcomes.
Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of
more than 100,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all
residents have the option of buying the test online.